Synthesis of $5-(\beta-D-glucopyranosyloxymethyl)-2'$ deoxyuridine and derivatives thereof. A modified dnucleoside from the DNA of *Trypanosoma brucei*

E.R. Wijsman, O. van den Berg, E. Kuyl-Yeheskiely, G.A. van der Marel and J.H. van Boom

Leiden Institute of Chemistry, Gorlaeus Laboratories, P.O. Box 9502, 2300 RA Leiden, The Netherlands

(Received April 27, 1994)

Abstract. An appropriately protected 3'-phosphoramidite and 5'-phosphate derivative of the modified 2'-deoxyuridine were obtained by β -glycosylation of a properly protected 5-hydroxyme-thyl-2'-deoxyuridine, and subsequent elaboration of the resulting intermediates using standard protocols devised in nucleic acids chemistry.

Trypanosoma brucei is a unicellular parasitic eukaryote transmitted by tsetse flies and causing sleeping sickness in mammals. The parasite can evade the immune response¹ of its mammalian host by antigenic variation of its surface coat, which is composed of only one protein species, the variant specific glycoprotein (VSG). The trypanosome genome contains numerous VSG genes that can be expressed one at a time in telomeric expression sites. Changing coat can occur either by replacing the VSG gene in the active site or by activating another expression site and turning the previously active off. How expression sites are switched on and off is still unclear. One of the mechanisms proposed² involves a specific telomeric DNA modification. Recently, Gommers-Ampt et al³. showed that 5-(β -D-glucopyranosyloxymethyl)-2'-deoxyuridine (i.e. compound 7) is a characteristic modified d-nucleoside of the DNA from T. brucei.

In order to gain a deeper insight in the biological function and conformational behaviour of DNA fragments containing at predetermined positions the rare d-nucleoside 7, we here present the first synthesis of the suitably protected phosphoramidite building unit 10 as well as the 5'-phosphate derivative 13. Prior to the preparation of the target molecules 10 and 13, we synthesized first, as outlined in Scheme 1, the naturally occurring compound 7. To this end, we examined whether the primary and secondary hydroxyl groups in the ribofuranosyl moiety of known 5-hydroxymethyl-2'-deoxyuridine⁴ (1a) could be silylated selectively with 1,3-dichlorotetraisopropyldisiloxane⁵ (TiPSCl₂). However, work up and purification of the reaction mixture, resulting after treatment of 1a with a slight excess of TiPSCl₂ in pyridine, gave the 3',5'-TiPS-derivative 3 in 30% yield. On the other hand, the fully protected compound 2 could be isolated in an excellent yield by silvlation of the 5-O-acetyl derivative 1b⁶ under the same conditions. Zemplén deacetylation of 2 proceeded smoothly to give the nucleosyl acceptor 3. Initially, the formation of the β -glycosidic linkage was elaborated by glycosylation of the allylic alcohol in 3 with the glycosyl donor ethyl 2,3,4,6-tetra-O-benzoyl-1-thio-B-D-glucopyranoside 4a. Unfortunately, condensation of 4a with 3 in the presence of N-iodo-succinimide and catalytic triflic acid⁷ led to an intractable mixture of products. However, glycosylation of 3 with the glycosyl bromide 4b under Helferich conditions⁸ resulted in the isolation of the expected B-linked product 5. Desilvlation of 5 followed by debenzoylation of 6 afforded, after gel filtration, homogeneous 7, the analytical data9 of which are in excellent accord with those reported³ for the naturally occurring minor d-nucleoside. Having the glucosylated and partially protected d-uridine 6 in hand, the introduction of the 5'-O-dimethoxytrityl protecting group and the 3'-Ocyanoethyl-phosphoramidite function was readily accomplished by the following standard two-step protocol¹⁰. Thus, tritylation of 6 with 4,4'-dimethoxytrityl chloride (DMT-Cl), and subsequent phosphitylation of 8 with reagent 9 gave the homogeneous target building unit 10 (³¹P NMR δ 149.2 & 149.13 ppm) in 49% overall yield. Furthermore, acetylation of 8 followed by detritylation¹¹ led to compound 11, the primary hydroxyl of which was phosphitylated with the new phosphitylating reagent 12¹²



Reagents and conditions:

i) TiPSCl₂, pyridine (90%); *ii*) KOtBu, MeOH, 30 min (60%); *iii*) Hg(CN)₂ - Hg(Br)₂, CH₃CN, 2 h (51%); *iv*) TBAF, pyridine-HCl, THF, 30 min (78%); *v*) KOtBu, MeOH, 16 h (91%); *vi*) DMT-Cl, pyridine, 1.5 h (71%); *vii*) 9, DiPEA, CH₂Cl₂, 30 min (70%); *viii*) Ac₂O, pyridine, DMAP, then pyrrole, CF₃COOH, CH₂Cl₂, 5 min. (97%); *ix*) 12, (2 eq), CH₂Cl₂, 1H tetrazole, 1 h; *x*) tBuOOH, 5 min (85%); *xi*) MeOH/dioxane/4N NaOH (5/14/1, v/v/v), 16 h (73%).

in the presence of 1H-tetrazole. *In-situ* oxidation of the resulting phosphitetriester intermediate 13 with *tert*butylhydroperoxide¹³ afforded the corresponding phosphotriester derivative 14 (³¹P NMR δ -1.8 ppm) in 85% yield based on 8. Removal of the benzoyl (Bz), acetyl and methylsulfonylethyl (Mse) groups from 8 was effected in one step with sodium hydroxide¹⁴ to give, after purification by gel filtration and further processing, homogeneous⁹ 15 (Na⁺-salt, ³¹P NMR δ 0.83 ppm) in 60% yield.

In conclusion, the results presented in this paper may open the way to the assembly of DNA, bearing at specific locations the β -glucosylated d-nucleoside 7, by either a solid-phase or enzymatic synthesis using the 3'-phosphoramidite 10 or 5'-phosphate 15, respectively, as the incoming building units.

Acknowledgement: We wish to thank Prof. P. Borst for his stimulating advice and the Netherlands Foundation for Chemical Research (SON) with the financial aid from the Netherlands Organization for the advancement of Pure Research (NWO) for financial support.

References and notes.

- 1. P. Borst, Immunology Today, 1991, 12, A29-A33.
- A. Bernards, N. van Harten-Loosbroek and P. Borst, Nucleic Acids Res., 1984, 12, 4153.
- J.H. Gommers-Ampt, F. van Leeuwen, A.L.J. de Beer, J.G.F. Vliegenthart, M. Dizdaroglu, J.A. Kowalak, P.F. Crain and P. Borst, *Cell*, 1993, 75, 129.
- G.T. Shiau, R.F. Schinazi, M.S. Chen and W.H. Prusoff, J. of Med. Chem., 1980, 23, 127. M.R. Conte, A. Galeone, D. Avizonis, V. Hsu, L. Mayol and D.R. Kearns, Bioorg. and Med. Chem. Lett., 1992, 2, 79.
- 5. W.T. Markiewicz, J. Chem. Res., 1979, 24.

- L.C. Sowers and G.P. Beardsley, J. Org. Chem., 1993, 58, 1664.
- 7. G.H. Veeneman, S.H. van Leeuwen and J.H. van Boom, *Tetrahedron Lett.*, **1990**, 31, 1331.
- 8. F. Weygand, H. Ziemann and H.J. Bestman, *Chem.* Ber. 1958, 91, 2534.
- Satisfactory mass spectrometric data were obtained for compounds 7, 10 and 15. Relevant ¹H and ¹³C NMR data (δ-values in ppm) for compounds 7 and 15.

7: ¹H NMR 300 MHz (D₂O): 8.02 (s, 1H, H-6 dU); 6.27 (t, 1H, H-1' dU, J 6.6 Hz); 4.63 (d, 1H, J 12.3 Hz, H-7, dU); 4.50 (d, 1H, $J_{1',2'}$ 7.8 Hz, H-1', dU); 3.27 (dd, $J_{2',3'}$, 9.2 Hz, H-2', Glu); 2.39 (m, 2H, H-2'and H-2'', dU).¹³C NMR (D₂O): 102.2 (C-1', Glu); 87.4 and 86.2 (C-4' and C-1', dU); 64.9, 61.8 and 61.4 (C-6', Glu, C-5'and C-7, dU).

15: ¹H NMR 400 MHz (D_2O): 8.08 (s, 1H, H-6, dU); 6.33 (t, 1H, $J_{1',2'}$ 6.8 and $J_{1',2''}$ 7.0 Hz, H-1', dU); 4.64 (d, 1H, J 12.1 Hz, H-7, dU); 4.54 (d, 1H, $J_{1'2'}$ 8.0 Hz, H-1', Glu); 2.39 (dd, 2H, H-2'and H-2'', dU). ¹³C (D_2O): 102.45 (C-1', Glu); 86.57 and 86.49 (C-4', dU, J_{pe} 8.5 Hz); 86.2 (C-1', dU).

- 10. N.D. Sinha, J. Biernat and H. Köster, Nucl. Acids Res., 1984, 12, 4539.
- 11. C.B. Reese, H.T. Serafinowska and G. Zappia, Tetrahedron Lett., 1986, 27, 2291.
- The phosphitylating reagent 12 (³¹P NMR δ 149.5 ppm) was readily accessible (cf. C.E. Dreef et al. Recl. Trav. Chim. Pays-Bas, 1987, 106, 161) by treatment of N,N-diisopropyl dichlorophosphoramidite in dry THF with a slight excess of methylsulfonylethanol in the presence of triethylamine.
- 13. J. Engels and A. Jäger, Angew. Chem. Suppl., 1982, 2010.
- 14. A. Beld, C.A.A. Claesen, E.S. Roersma, W.J.M. Schippers, L.M. Keizer and G.I. Tesser, *Recl. Trav. Chim. Pays-Bas*, 1984, 103, 196.